The Breast Cancer Update You Missed: Three New SERDs Just Changed Treatment
If you have estrogen receptor positive, HER2 negative breast cancer, the standard of care just changed — and most oncologists haven't caught up yet. Three new drugs, vepdegestrant, camizestrant, and giredestrant, just outperformed the 25-year breast cancer standard in Phase 3 clinical trials. Understanding ESR1 mutations, aromatase inhibitor resistance, and liquid biopsy testing now directly affects which treatment you should be on and when.
Why Aromatase Inhibitors Stop Working — The ESR1 Mutation Problem
When you block estrogen with an aromatase inhibitor, tumor cells quit growing and some die. But a small number carry a mutation that lets the estrogen receptor activate itself without estrogen at all. That cell survives, multiplies rapidly, and eventually takes over. This is an ESR1 activating mutation and it develops in approximately 40 to 50 percent of patients who progress on aromatase inhibitors plus CDK4/6 inhibitors. Once it happens, blocking estrogen is irrelevant. You are getting all the side effects with none of the benefit.
The Old SERD Standard — And Why It's Now the Weak Comparator
Fulvestrant has been the only approved SERD for almost 25 years. It binds to the estrogen receptor and marks it for disposal, but the process is inefficient. Even at maximum dose it achieves only 50 to 80 percent receptor suppression. In ESR1 mutant disease it produces a median progression free survival of just 2.1 months. It was the best available option for a very long time. It is now the arm that every new drug beats.
Vepdegestrant: A New Mechanism That's Already Available
Vepdegestrant works through a completely new mechanism called a PROTAC. It actively recruits the cell's disposal machinery, tags the estrogen receptor directly, and sends it to be destroyed immediately. The PROTAC itself is then released undamaged and goes to find another receptor — catalytic degradation. The VERITAC-2 trial showed a 43 percent reduction in risk of progression or death in ESR1 mutant disease and nearly five times the tumor response rate of fulvestrant. It is an oral daily pill, already FDA approved, available right now.
Camizestrant and Giredestrant: Two Different Clocks
Camizestrant targets patients still on first line therapy whose liquid biopsy detects an emerging ESR1 mutation before clinical progression. The SERENA-6 trial showed a 56 percent reduction in risk of progression or death by switching proactively. Giredestrant goes further — the LIDRA trial showed a 30 percent reduction in recurrence risk in early stage breast cancer patients, beating tamoxifen and aromatase inhibitors in adjuvant treatment for the first time in 25 years. Neither is FDA approved yet, but giredestrant has a decision date by mid-December 2026.
The One Question to Ask Your Oncologist Now
Have you been tested for ESR1 mutations? If you have been on an aromatase inhibitor plus a CDK4/6 inhibitor, there is a real probability the mutation has already developed. Ask specifically — if not, why not?
Accurate science saves lives — and it starts with rejecting simple myths in favor of real understanding. Stay curious.
Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace guidance from your healthcare provider. Cancer and treatment decisions are highly individual—always consult your physician or qualified healthcare professional regarding your specific situation.
A full disclaimer is available Terms and Conditions.